To the Editor: Schmidt et al. (Feb. 10 issue)1 credit foscarnettherapy with the favorable outcome in a patient infected withthe human immunodeficiency virus (HIV) who had Epstein–Barrvirus (EBV)–associated polyclonal B-cell lymphoproliferation.This interpretation is surprising, since the use of highly activeantiretroviral therapy is more likely to account for the tumorregression. The patient had received highly active antiretroviraltherapy (zidovudine, lamivudine, and saquinavir) for only fourweeks before presentation and started highly active antiretroviraltherapy with four drugs (stavudine, lamivudine, saquinavir,and ritonavir) after a break of just one week. This treatmentwas effective, reducing the . . . [Full Text of this Article]
Previous
